NCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
Clinical Trials
8 trialsNCT05101148 2026-02-23
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
AstraZeneca
Phase 1 Active not recruiting
NCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
NCT04590235 2026-01-30
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
Phase 1 Active not recruiting
NCT05363267 2026-01-13
NF-1, Nutraceutical Intervention
Masonic Cancer Center, University of Minnesota
Phase 1 Active not recruiting
NCT06961565 2025-12-04
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Phase 1 Recruiting
NCT06132165 2025-11-21
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT06300502 2025-11-20
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Phase 1 Enrolling by invitation